OCD

Does insight have specific correlation with symptom dimensions in OCD?

Cherian AV, Narayanaswamy JC, Srinivasaraju R, Viswanath B, Math SB, Kandavel T, et al. Does insight have specific correlation with symptom dimensions in OCD?. J Affect Disord. 2012;138(3):352-9. DOI: 10.1016/j.jad.2012.01.017. PubMed PMID: 22331022.

Behavioral pattern analysis and dopamine release in quinpirole-induced repetitive behavior in rats.

de Haas R, Nijdam A, Westra TA, Kas MJH, Westenberg HGM. Behavioral pattern analysis and dopamine release in quinpirole-induced repetitive behavior in rats. J Psychopharmacol. 2011;25(12):1712-9. DOI: 10.1177/0269881110389093. PubMed PMID: 21148023.

Cross-sectional comparison of the clinical characteristics of adults with early-onset and late-onset obsessive compulsive disorder.

Wang X, Cui D, Wang Z, Fan Q, Xu H, Qiu J, et al. Cross-sectional comparison of the clinical characteristics of adults with early-onset and late-onset obsessive compulsive disorder. J Affect Disord. 2012;136(3):498-504. DOI: 10.1016/j.jad.2011.11.001. PubMed PMID: 22119088.

Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.

Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011;306(11):1224-32. DOI: 10.1001/jama.2011.1344. PubMed PMID: 21934055; PubMed Central PMCID: PMC3495326.

The impact of depression on the treatment of obsessive-compulsive disorder: results from a 5-year follow-up.

Anholt GE, Aderka IM, van Balkom AJLM, Smit JH, Hermesh H, de Haan E, et al. The impact of depression on the treatment of obsessive-compulsive disorder: results from a 5-year follow-up. J Affect Disord. 2011;135(1-3):201-7. DOI: 10.1016/j.jad.2011.07.018. PubMed PMID: 21889802.

Brain regional α-[11C]methyl-L-tryptophan trapping in medication-free patients with obsessive-compulsive disorder.

Berney A, Leyton M, Gravel P, Sibon I, Sookman D, Rosa Neto P, et al. Brain regional α-[11C]methyl-L-tryptophan trapping in medication-free patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 2011;68(7):732-41. DOI: 10.1001/archgenpsychiatry.2011.16. PubMed PMID: 21383250; PubMed Central PMCID: PMC3677917.

Co-occurrence of obsessive-compulsive disorder and substance use disorder in the general population.

Blom RM, Koeter M, van den Brink W, de Graaf R, ten Have M, Denys D. Co-occurrence of obsessive-compulsive disorder and substance use disorder in the general population. Addiction. 2011;106(12):2178-85. DOI: 10.1111/j.1360-0443.2011.03559.x. PubMed PMID: 21714825.

Genoa Neuropsychiatric Pharmacy Learning Module: Anxiety Disorders (OCD/GAD, PTSD, Panic)

At the end of this program, the participant should be able to:

  1. Evaluate whether the patient meets DSM-IV-TR criteria for an anxiety disorder [generalized anxiety disorder (GAD), panic disorder, obsessive-compulsive disorder (OCD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD)] given a case example.
  2. Interpret common rating scales in the evaluation and management of anxiety disorders.
  3. Distinguish differences in pharmacology, kinetics, efficacy, dosing, adverse effects, and drug interactions of benzodiazepines in the management of anxiety disorders.
  4. Compare the efficacy, dosing, and adverse effects of the serotonergic antidepressants, and the role of antipsychotics in the management of anxiety disorders.
  5. Evaluate whether patient and professional education is optimal to facilitate safe and effective drug therapy for anxiety disorders. (DII)
  6. Using practice guidelines, develop a pharmacotherapy plan, including dosing and duration of therapy, and nonpharmacologic treatments, for a patient with anxiety disorders.
  7. Discuss the role of pharmacotherapy in the management of anxiety disorders in special populations (e.g., children, elderly patients and pregnancy).
  8. Resolve potential drug-related problems in patients with anxiety disorders.
Read more about this session.

A multivariate twin study of obsessive-compulsive symptom dimensions.

Iervolino AC, Rijsdijk FV, Cherkas L, Fullana MA, Mataix-Cols D. A multivariate twin study of obsessive-compulsive symptom dimensions. Arch Gen Psychiatry. 2011;68(6):637-44. DOI: 10.1001/archgenpsychiatry.2011.54. PubMed PMID: 21646580.

Complementary medicine, self-help, and lifestyle interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review.

Sarris J, Camfield D, Berk M. Complementary medicine, self-help, and lifestyle interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review. J Affect Disord. 2012;138(3):213-21. DOI: 10.1016/j.jad.2011.04.051. PubMed PMID: 21620478.